Improving API lung permeability using hyperthermia

Larissa Gomes dos Reis; Dina M. Silva; Daniela Traini; Vitor Sencadas

Improving API lung permeability using hyperthermia

Larissa Gomes dos Reis, Dina M. Silva, Daniela Traini, Vitor Sencadas

Research output: Chapter in Book/Report/Conference proceeding › Conference proceeding contribution › peer-review

Abstract

After an active pharmaceutical ingredient (API) is aerosolized and deposited in the lung, the API needs to be dissolved and transported across the pulmonary epithelia to exert its therapeutic effect. API permeability is considered a major drawback for achieving adequate treatment efficacy, and an important predictor of effect duration for locally-acting drugs, due to its correlation with local residence time. In the past few years, the use of hyperthermia (defined as elevated core temperature >38.5°C) has risen as a potential complementary tool to increase API permeability, and consequently for enhancing the efficacy of delivered drugs. Specifically for lung therapies, the effects of this increase in temperature has been investigated mostly for the treatment of lung cancer and restricted to increasing cytotoxicity to lung cancer cells, with no studies on drug permeability. This study aims to investigate the effect of hyperthermia on the permeability of inhaled APIs across lung epithelia.

Original language	English
Title of host publication	Respiratory Drug Delivery 2020
Editors	R. N. Dalby, P. R. Byron, M. Hindle, J. Peart, D. Traini, P. M. Young, S. J. Farr, J. D. Suman, A. Watts
Place of Publication	Richmond, VA
Publisher	RDD Online
Pages	749-752
Number of pages	4
Volume	3
ISBN (Electronic)	9781942911487
Publication status	Published - 2020
Externally published	Yes
Event	Respiratory Drug Delivery 2020 - Palm Desert, United States Duration: 26 Apr 2020 → 30 Apr 2020

Conference

Conference	Respiratory Drug Delivery 2020
Country/Territory	United States
City	Palm Desert
Period	26/04/20 → 30/04/20

Keywords

active pharmaceutical ingredient (API)
permeability
salbutamol sulphate
Calu-3 cells
hyperthermia
transporters

Access to Document

https://www.rddonline.com/rdd/article.php?id=0&sid=103&ArticleID=2766&return=1

Cite this

Gomes dos Reis, L., Silva, D. M., Traini, D., & Sencadas, V. (2020). Improving API lung permeability using hyperthermia. In R. N. Dalby, P. R. Byron, M. Hindle, J. Peart, D. Traini, P. M. Young, S. J. Farr, J. D. Suman, & A. Watts (Eds.), Respiratory Drug Delivery 2020 (Vol. 3, pp. 749-752). RDD Online. https://www.rddonline.com/rdd/article.php?id=0&sid=103&ArticleID=2766&return=1

@inproceedings{6d9f3b73e2ce467bacb6a6947bd01baa,

title = "Improving API lung permeability using hyperthermia",

abstract = "After an active pharmaceutical ingredient (API) is aerosolized and deposited in the lung, the API needs to be dissolved and transported across the pulmonary epithelia to exert its therapeutic effect. API permeability is considered a major drawback for achieving adequate treatment efficacy, and an important predictor of effect duration for locally-acting drugs, due to its correlation with local residence time. In the past few years, the use of hyperthermia (defined as elevated core temperature >38.5°C) has risen as a potential complementary tool to increase API permeability, and consequently for enhancing the efficacy of delivered drugs. Specifically for lung therapies, the effects of this increase in temperature has been investigated mostly for the treatment of lung cancer and restricted to increasing cytotoxicity to lung cancer cells, with no studies on drug permeability. This study aims to investigate the effect of hyperthermia on the permeability of inhaled APIs across lung epithelia.",

keywords = "active pharmaceutical ingredient (API), permeability, salbutamol sulphate, Calu-3 cells, hyperthermia, transporters",

author = "{Gomes dos Reis}, Larissa and Silva, {Dina M.} and Daniela Traini and Vitor Sencadas",

year = "2020",

language = "English",

volume = "3",

pages = "749--752",

editor = "Dalby, {R. N.} and Byron, {P. R.} and M. Hindle and J. Peart and D. Traini and Young, {P. M.} and Farr, {S. J.} and Suman, {J. D.} and A. Watts",

booktitle = "Respiratory Drug Delivery 2020",

publisher = "RDD Online",

note = "Respiratory Drug Delivery 2020 ; Conference date: 26-04-2020 Through 30-04-2020",

}

Gomes dos Reis, L, Silva, DM, Traini, D & Sencadas, V 2020, Improving API lung permeability using hyperthermia. in RN Dalby, PR Byron, M Hindle, J Peart, D Traini, PM Young, SJ Farr, JD Suman & A Watts (eds), Respiratory Drug Delivery 2020. vol. 3, RDD Online, Richmond, VA, pp. 749-752, Respiratory Drug Delivery 2020, Palm Desert, California, United States, 26/04/20. <https://www.rddonline.com/rdd/article.php?id=0&sid=103&ArticleID=2766&return=1>

Improving API lung permeability using hyperthermia. / Gomes dos Reis, Larissa; Silva, Dina M.; Traini, Daniela et al.
Respiratory Drug Delivery 2020. ed. / R. N. Dalby; P. R. Byron; M. Hindle; J. Peart; D. Traini; P. M. Young; S. J. Farr; J. D. Suman; A. Watts. Vol. 3 Richmond, VA: RDD Online, 2020. p. 749-752.

Research output: Chapter in Book/Report/Conference proceeding › Conference proceeding contribution › peer-review

TY - GEN

T1 - Improving API lung permeability using hyperthermia

AU - Gomes dos Reis, Larissa

AU - Silva, Dina M.

AU - Traini, Daniela

AU - Sencadas, Vitor

PY - 2020

Y1 - 2020

N2 - After an active pharmaceutical ingredient (API) is aerosolized and deposited in the lung, the API needs to be dissolved and transported across the pulmonary epithelia to exert its therapeutic effect. API permeability is considered a major drawback for achieving adequate treatment efficacy, and an important predictor of effect duration for locally-acting drugs, due to its correlation with local residence time. In the past few years, the use of hyperthermia (defined as elevated core temperature >38.5°C) has risen as a potential complementary tool to increase API permeability, and consequently for enhancing the efficacy of delivered drugs. Specifically for lung therapies, the effects of this increase in temperature has been investigated mostly for the treatment of lung cancer and restricted to increasing cytotoxicity to lung cancer cells, with no studies on drug permeability. This study aims to investigate the effect of hyperthermia on the permeability of inhaled APIs across lung epithelia.

AB - After an active pharmaceutical ingredient (API) is aerosolized and deposited in the lung, the API needs to be dissolved and transported across the pulmonary epithelia to exert its therapeutic effect. API permeability is considered a major drawback for achieving adequate treatment efficacy, and an important predictor of effect duration for locally-acting drugs, due to its correlation with local residence time. In the past few years, the use of hyperthermia (defined as elevated core temperature >38.5°C) has risen as a potential complementary tool to increase API permeability, and consequently for enhancing the efficacy of delivered drugs. Specifically for lung therapies, the effects of this increase in temperature has been investigated mostly for the treatment of lung cancer and restricted to increasing cytotoxicity to lung cancer cells, with no studies on drug permeability. This study aims to investigate the effect of hyperthermia on the permeability of inhaled APIs across lung epithelia.

KW - active pharmaceutical ingredient (API)

KW - permeability

KW - salbutamol sulphate

KW - Calu-3 cells

KW - hyperthermia

KW - transporters

M3 - Conference proceeding contribution

VL - 3

SP - 749

EP - 752

BT - Respiratory Drug Delivery 2020

A2 - Dalby, R. N.

A2 - Byron, P. R.

A2 - Hindle, M.

A2 - Peart, J.

A2 - Traini, D.

A2 - Young, P. M.

A2 - Farr, S. J.

A2 - Suman, J. D.

A2 - Watts, A.

PB - RDD Online

CY - Richmond, VA

T2 - Respiratory Drug Delivery 2020

Y2 - 26 April 2020 through 30 April 2020

ER -

Improving API lung permeability using hyperthermia

Abstract

Conference

Keywords

Access to Document

Fingerprint

Cite this